Jubilant Life Sciences is currently trading at Rs. 730.90, up by 38.35 points or 5.54% from its previous closing of Rs. 692.55 on the BSE.
The scrip opened at Rs. 700.00 and has touched a high and low of Rs. 739.40 and Rs. 691.60 respectively. So far 166078 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 879.10 on 12-Apr-2017 and a 52 week low of Rs. 552.40 on 26-Dec-2016.
Last one week high and low of the scrip stood at Rs. 739.40 and Rs. 634.15 respectively. The current market cap of the company is Rs. 11659.38 crore.
The promoters holding in the company stood at 54.02% while Institutions and Non-Institutions held 24.66% and 21.32% respectively.
Jubilant Life Sciences has received approval from Centre’s green panel for setting up a technical grade pesticide manufacturing unit in Gujarat, which would entail an investment of Rs 250 crore. The company’s proposal is to establish a unit for manufacturing 30-odd technical grade pesticides and intermediates with a production capacity of 32,350 tonnes per annum.
The Expert Appraisal Committee (EAC) recommended environment clearance to the proposed project subject to compliance to certain conditions. The proposed unit will be set up in an area of 20 hectare in Vagra taluk of Bharuch district.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: